Free shipping on all orders over $ 500

Ametumumab

Cat. No. M40597
Ametumumab Structure
Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ametumumab is a recombinant fully human anti-EGFR monoclonal antibody that can be used in studies related to colorectal cancer.

Chemical Information
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] S Rao et al. Ann Oncol. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

[2] Axel Kleespies et al. Clin Cancer Res. Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine

[3] Judith Schmiedel et al. Cancer Cell. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization

[4] Joan H Schiller. Cancer Invest. Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000)

[5] Fernando Rivera et al. Acta Oncol. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

Related EGFR/HER2 Products
Zongertinib

Zongertinib (BI 1810631) is a human HER2-selective tyrosine kinase inhibitor that covalently binds to both wild-type and mutated HER2 receptors, including exon 20 insertion mutations, whilst sparing EGFR signaling. Zongertinib has antitumor activity.

Inetetamab

Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab shows antitumor activities when used alone or together with tyrosine kinase inhibitors.

BBT-207

BBT-207 is a reversible, mutant-specific EGFR inhibitor with antitumor activity.

VRN-11

VRN-11 is an EGFR C797S inhibitor.

TRX-221

TRX-221 is an EGFR C797S inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: Ametumumab supplier, EGFR/HER2, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.